Related Experiment Video
Updated: Jan 19, 2026
Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
Published on: April 26, 2024
New Frontiers in Osteoporosis Therapy
Cheng Cheng1,2, Kelly Wentworth2,3, Dolores M Shoback1,2
1Endocrine Research Unit, Endocrine-Metabolism Section, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA;
Abstract:
Current osteoporosis medications reduce fractures significantly but have rare and serious adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their safety for long-term use. Insights from basic bone biology and genetic disorders have led to recent advances in therapeutics for osteoporosis. New approaches now in clinical use include the antisclerostin monoclonal antibody romosozumab, as well as the parathyroid hormone-related peptide analog abaloparatide. Clinical trial data show significant antifracture benefits with recently approved romosozumab. Studies using abaloparatide build on our longstanding experience with teriparatide and the importance of consolidating the bone mineral density gains achieved from an anabolic agent by following it with an antiresorptive. Combination and sequential treatments using osteoporosis medications with different mechanisms of action have also been tested with promising results. On the horizon is the potential for cell-based therapies (e.g., mesenchymal stem cells) and drugs that target the elimination of senescent cells in the bone microenvironment.
Insights
New osteoporosis therapies like romosozumab and abaloparatide offer significant fracture reduction. Future treatments may include cell-based therapies and senolytics for improved bone health.
Area of Science:
- Bone biology and genetics
- Pharmacology
- Regenerative medicine
Background:
- Current osteoporosis drugs have rare but severe side effects, limiting long-term use.
- Advances in bone biology and genetics are driving new therapeutic strategies.
- Osteoporosis management requires balancing efficacy with safety concerns.
Purpose of the Study:
- To review recent advances in osteoporosis therapeutics.
- To highlight novel anabolic agents and combination treatment strategies.
- To discuss emerging cell-based and senolytic therapies.
Main Methods:
- Review of clinical trial data for romosozumab and abaloparatide.
- Analysis of sequential and combination treatment approaches.
- Exploration of preclinical and emerging therapeutic concepts.
Main Results:
- Romosozumab demonstrates significant antifracture benefits.
- Abaloparatide builds on teriparatide experience, emphasizing consolidation of gains.
- Combination and sequential therapies show promising results.
Conclusions:
- Novel agents like romosozumab and abaloparatide represent significant progress in osteoporosis treatment.
- Strategic use of anabolic agents followed by antiresorptives is crucial.
- Future research directions include cell-based therapies and senolytics for bone regeneration and microenvironment modulation.
Related Concept Videos
03:56Operation Procedure and Precautions of Lingnan Fire-Needle Therapy in Osteoporosis Model Rats
06:59Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model
01:15Production Possibility Frontier (PPF)
The PPF assumes that resources are fixed and fully employed and technology remains constant. Any point on the curve represents a combination of goods that fully utilizes available resources.
Points inside the curve indicate...
01:25Derivation of Production Possibility Frontier
07:20Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
00:59Gene Therapy